Dizal Pharmaceutical Co (SHSE:688192) EBIT: ¥-639.4 Mil (TTM As of Mar. 2026)


SHSE:688192 Dizal Pharmaceutical Co Ltd SHSE:688192
36 GF Score
Price ¥36.49
GF Value ¥132.14
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Dizal Pharmaceutical Co EBIT?

Dizal Pharmaceutical Co SHSE:688192 -6.56% 36 EBIT is ¥-639.4 Mil as of Mar. 2026. GuruFocus rates SHSE:688192 with a GF Score™ of 36/100 and a GF Value™ of ¥132.14 (Possible Value Trap). The stock has 4 warning signs investors should review.

Dizal Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥-88.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-639.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Dizal Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2026 was -29.11%. Dizal Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -93.79%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Dizal Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -3.88%.

Dizal Pharmaceutical Co  (SHSE:688192) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Dizal Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-382.852 * ( 1 - 0% )/( (1355.98 + 1274.277)/ 2 )
=-382.852/1315.1285
=-29.11 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3002.529 - 449.106 - ( 1936.261 - max(0, 985.234 - 2182.677+1936.261))
=1355.98

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3013.02 - 314.773 - ( 1934.235 - max(0, 782.359 - 2206.329+1934.235))
=1274.277

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Dizal Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-354.984/( ( (381.231 + max(-211.504, 0)) + (375.718 + max(-52.895, 0)) )/ 2 )
=-354.984/( ( 381.231 + 375.718 )/ 2 )
=-354.984/378.4745
=-93.79 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(143.441 + 36.949 + 62.716) - (449.106 + 0 + 5.504)
=-211.504

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(170.99 + 32.137 + 65.6) - (314.773 + 0 + 6.849)
=-52.895

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Dizal Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-639.412/16486.481
=-3.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dizal Pharmaceutical Co EBIT Related Terms

Dizal Pharmaceutical Co EBIT Historical Data

* Premium members only.

The historical data trend for Dizal Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dizal Pharmaceutical Co EBIT Chart

Dizal Pharmaceutical Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -666.81 -731.40 -1,100.04 -916.90 -735.91

Dizal Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -185.25 -176.59 -197.47 -176.60 -88.75

SHSE:688192 vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Dizal Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dizal Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dizal Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dizal Pharmaceutical Co's EV-to-EBIT falls into.


SHSE:688192
36GF Score
Dizal Pharmaceutical Co Ltd SHSE:688192
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dizal Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-639.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥-639.4 Mil mean?
Dizal Pharmaceutical Co (SHSE:688192) has a EBIT of ¥-639.4 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dizal Pharmaceutical Co.
Is Dizal Pharmaceutical Co's EBIT too high?
Dizal Pharmaceutical Co's current EBIT is ¥-639.4 Mil. Overall, Dizal Pharmaceutical Co has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dizal Pharmaceutical Co's EBIT compare to ZTS?
Dizal Pharmaceutical Co's EBIT of ¥-639.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dizal Pharmaceutical Co. Dizal Pharmaceutical Co's current EBIT is ¥-639.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dizal Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Dizal Pharmaceutical Co (SHSE:688192) is currently considered Possible Value Trap. The stock's GF Value™ is ¥132.14, compared to a current price of ¥36.49 — trading 72.4% below its estimated fair value. The current EBIT is ¥-639.4 Mil. Dizal Pharmaceutical Co's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Dizal Pharmaceutical Co (SHSE:688192), the current EBIT is ¥-639.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dizal Pharmaceutical Co (SHSE:688192) Overvalued in 2026?

Based on GuruFocus' analysis, Dizal Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥36.49 is trading 72.4% below its estimated GF Value™ of ¥132.14. GuruFocus considers Dizal Pharmaceutical Co to be Possible Value Trap.

Key valuation signals for SHSE:688192:

  • EBIT: ¥-639.4 Mil
  • GF Value™: ¥132.14 vs. price of ¥36.49 (72.4% below fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dizal Pharmaceutical Co Business Description

Address Jinghui East Road, Room 4105, Building E (Building 5), Huirong Business Plaza, Xinwu District, Jiangsu Province, Wuxi City, CHN, 201203
Dizal Pharmaceutical Co Ltd, formerly Dizal (Jiangsu) Pharmaceutical Co Ltd is engaged in the research and development, production and sales of innovative drugs.
36GF Score

Get the complete analysis for SHSE:688192

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥36.49
Price
¥132.14
GF Value